Julien Milon Essola , Haiyin Yang , Wenjing Liu , Abid Hussain , Abid Naeem , Huining He , Stefan Barth , Zhuoran Wang , Kelong Fan , Mengjie Zhang , Mengliang Zhu , Xing-Jie Liang , Yuanyu Huang
{"title":"用于siRNA传递和协同癌症治疗的肿瘤抑制蛋白激发肽","authors":"Julien Milon Essola , Haiyin Yang , Wenjing Liu , Abid Hussain , Abid Naeem , Huining He , Stefan Barth , Zhuoran Wang , Kelong Fan , Mengjie Zhang , Mengliang Zhu , Xing-Jie Liang , Yuanyu Huang","doi":"10.1016/j.fmre.2025.03.006","DOIUrl":null,"url":null,"abstract":"<div><div>Small interfering RNA (siRNA) has shown promising therapeutic prospects in many major diseases. However, two main reasons limit the application of siRNA: poor endocytosis efficiency and weak endosomal escape ability. Therefore, the development of efficient and safe delivery vectors has always been an important study aspect of RNAi technology. Herein, we designed a self-assembled nanoparticle based on functionalized peptides to deliver siRNA to the down-regulated polo-like kinase 1 (PLK1) gene, which can inhibit tumor cells in the G2 phase. The functional polypeptide consists of cell membrane-penetrating peptide (CPP44) and p16 minimal inhibitory sequence (p16MIS). CPP44 can effectively mediate endocytosis, while p16MIS can inhibit tumor growth in the G1 phase and synergistically promote the apoptosis of tumor cells with siPLK1. <em>In vitro</em> and <em>in vivo</em> studies demonstrate that the developed nanoparticle exhibits high levels of silencing efficiency, antitumor activity, and therapeutic efficacy. Consequently, this study provides a novel approach to cancer treatment by simultaneously disrupting two stages of tumor cell division.</div></div>","PeriodicalId":34602,"journal":{"name":"Fundamental Research","volume":"5 5","pages":"Pages 1920-1929"},"PeriodicalIF":6.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy\",\"authors\":\"Julien Milon Essola , Haiyin Yang , Wenjing Liu , Abid Hussain , Abid Naeem , Huining He , Stefan Barth , Zhuoran Wang , Kelong Fan , Mengjie Zhang , Mengliang Zhu , Xing-Jie Liang , Yuanyu Huang\",\"doi\":\"10.1016/j.fmre.2025.03.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Small interfering RNA (siRNA) has shown promising therapeutic prospects in many major diseases. However, two main reasons limit the application of siRNA: poor endocytosis efficiency and weak endosomal escape ability. Therefore, the development of efficient and safe delivery vectors has always been an important study aspect of RNAi technology. Herein, we designed a self-assembled nanoparticle based on functionalized peptides to deliver siRNA to the down-regulated polo-like kinase 1 (PLK1) gene, which can inhibit tumor cells in the G2 phase. The functional polypeptide consists of cell membrane-penetrating peptide (CPP44) and p16 minimal inhibitory sequence (p16MIS). CPP44 can effectively mediate endocytosis, while p16MIS can inhibit tumor growth in the G1 phase and synergistically promote the apoptosis of tumor cells with siPLK1. <em>In vitro</em> and <em>in vivo</em> studies demonstrate that the developed nanoparticle exhibits high levels of silencing efficiency, antitumor activity, and therapeutic efficacy. Consequently, this study provides a novel approach to cancer treatment by simultaneously disrupting two stages of tumor cell division.</div></div>\",\"PeriodicalId\":34602,\"journal\":{\"name\":\"Fundamental Research\",\"volume\":\"5 5\",\"pages\":\"Pages 1920-1929\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fundamental Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266732582500113X\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Multidisciplinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266732582500113X","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}
Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy
Small interfering RNA (siRNA) has shown promising therapeutic prospects in many major diseases. However, two main reasons limit the application of siRNA: poor endocytosis efficiency and weak endosomal escape ability. Therefore, the development of efficient and safe delivery vectors has always been an important study aspect of RNAi technology. Herein, we designed a self-assembled nanoparticle based on functionalized peptides to deliver siRNA to the down-regulated polo-like kinase 1 (PLK1) gene, which can inhibit tumor cells in the G2 phase. The functional polypeptide consists of cell membrane-penetrating peptide (CPP44) and p16 minimal inhibitory sequence (p16MIS). CPP44 can effectively mediate endocytosis, while p16MIS can inhibit tumor growth in the G1 phase and synergistically promote the apoptosis of tumor cells with siPLK1. In vitro and in vivo studies demonstrate that the developed nanoparticle exhibits high levels of silencing efficiency, antitumor activity, and therapeutic efficacy. Consequently, this study provides a novel approach to cancer treatment by simultaneously disrupting two stages of tumor cell division.